Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164455 | 1.00 | CDK2 (0.36) | CDK2CCNE1CDK1FLT3CDK9 | |
| SCHEMBL20164427 | 1.00 | CDK2 (0.36) | CDK2CCNE1CDK1FLT3CDK9 | |
| Hydrochloric Acid SCHEMBL20164434 | 0.99 | CDK2 (0.35) | CDK2CCNE1CDK1FLT3CDK9 | |
| Hydrochloric Acid SCHEMBL20164436 | 0.99 | CDK2 (0.35) | CDK2CCNE1CDK1FLT3CDK9 | |
| Hydrochloric Acid SCHEMBL20164628 | 0.99 | CDK2 (0.35) | CDK2CCNE1CDK1FLT3CDK9 | |
| SCHEMBL20164318 | 0.87 | CDK2 (0.38) | CDK2CCNE1CDK1FLT3CDK9 | |
| SCHEMBL20164653 | 0.87 | CDK2 (0.38) | CDK2CCNE1CDK1FLT3CDK9 | |
| SCHEMBL20164317 | 0.87 | CDK2 (0.38) | CDK2CCNE1CDK1FLT3CDK9 | |
| Hydrochloric Acid SCHEMBL20164546 | 0.86 | CDK2 (0.37) | CDK2CCNE1CDK1FLT3CDK9 | |
| Hydrochloric Acid SCHEMBL20164473 | 0.86 | CDK2 (0.37) | CDK2CCNE1CDK1FLT3CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | claimed |
| US-20250057848-A1 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2025-02-20 | — | — | US | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | CDK2 4026/4885CCNE1 4167/4885CDK1 3077/4885 |
| US-20250057848-A1 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | GPR119, GPR35, GPR55 | CDK2 3942/4885CCNE1 2993/4885CDK1 3085/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | CDK2 4190/4885CCNE1 4321/4885CDK1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.